Iron Homeostasis: How Hepcidin Balances Iron Absorption and Storage

A Double-Edged Element: Why Iron Balance Is So Dangerous

Iron occupies a unique and precarious position in human physiology. As the core of the heme molecule in hemoglobin and myoglobin, it is absolutely required to bind and transport oxygen to every tissue in the body, and it also serves as a cofactor for enzymes involved in DNA synthesis and cellular energy production. But the same chemical property that makes iron useful, its ability to readily accept and donate electrons, also makes it hazardous. Free or loosely bound iron can drive the Fenton reaction, generating hydroxyl radicals that damage lipids, proteins, and DNA. Too little iron starves the bone marrow of the raw material for hemoglobin, producing the fatigue, pallor, and shortness of breath of iron-deficiency anemia. Too much iron, especially when it exceeds the capacity of transport and storage proteins, leads to deposition in the liver, heart, pancreas, and joints, causing cirrhosis, heart failure, diabetes, and arthritis over years of accumulation. The critical complication is that the body cannot simply excrete surplus iron the way it eliminates excess sodium or urea through the kidneys. Iron lost through sweat, sloughed skin, and intestinal cells amounts to roughly one to two milligrams per day in a healthy adult, a fixed and largely unregulated loss. Because there is no adjustable excretory valve, the only place the body can meaningfully control iron balance is at the point of entry, in the small intestine, where dietary iron either crosses into the bloodstream or is lost when the intestinal cell sloughs off days later. This is why the hormonal system governing absorption carries such outsized physiological importance.

The Discovery of Hepcidin: A Master Regulatory Hormone

Hepcidin was identified in the early 2000s, first isolated from human urine and blood as a small antimicrobial peptide, and initially named for its liver origin (hepar) and bactericidal properties (-cidin). Researchers soon discovered its far more consequential role as the central regulator of systemic iron metabolism, a finding that reorganized the entire field of iron physiology around a single hormonal axis. Hepcidin is a 25-amino-acid peptide synthesized primarily by hepatocytes in the liver, and its production is tuned by multiple inputs: it rises when body iron stores are high, when inflammation is present, and it falls when iron stores are low, when erythropoiesis (red blood cell production) is accelerated, or when oxygen levels drop. The liver essentially functions as the body's iron sensor, integrating signals from circulating transferrin-bound iron, from stored iron reflected by ferritin, and from cytokines such as interleukin-6 released during infection or inflammation. Once secreted into the bloodstream, hepcidin travels to its targets and directly controls how much iron enters circulation, rather than how much iron is present in the diet. This discovery explained a long-standing puzzle in medicine: why patients with chronic infections, autoimmune disease, or cancer often develop anemia despite having adequate or even elevated iron stores. The answer lay in persistently elevated hepcidin driven by inflammatory signaling, a mechanism that reframed anemia of chronic disease as a hormonal disorder of iron distribution rather than a simple deficiency.

Ferroportin: The Only Known Gate for Cellular Iron Export

Ferroportin is the sole protein known to export iron out of cells and into the bloodstream, making it the single chokepoint through which nearly all dietary and recycled iron must pass. It is expressed at high density on three key cell types: duodenal enterocytes that absorb dietary iron, macrophages that recycle iron from aged red blood cells, and hepatocytes that release stored iron when needed. Hepcidin acts directly on ferroportin by binding to it, triggering its internalization and degradation inside the cell. When hepcidin is high, ferroportin molecules are pulled from the cell surface and destroyed, trapping iron inside enterocytes and macrophages where it cannot reach the blood. Since intestinal cells are shed and replaced every few days, iron trapped in an enterocyte is effectively lost to the body when that cell sloughs into the gut lumen. When hepcidin is low, ferroportin remains stable on the cell surface, and iron flows freely into the plasma. This elegant single-hormone, single-receptor system explains why dietary iron absorption is normally so limited: even in a healthy diet, only about 10 to 15 percent of ingested iron is actually absorbed, with the rest passing through the gut unabsorbed. Absorption efficiency can rise several-fold when hepcidin is suppressed, such as during iron deficiency or increased demand for red blood cell production, and can fall to near zero when hepcidin is strongly elevated during acute inflammation. Because macrophages recycle roughly 20 to 25 milligrams of iron daily from breaking down old red blood cells, far more than the one to two milligrams typically absorbed from food, ferroportin's control over macrophage iron release is at least as important for day-to-day iron supply as its control over gut absorption.

Transferrin and Ferritin: Moving and Storing Iron Safely

Because free iron is toxic, the body never allows meaningful amounts to circulate unbound; instead, two specialized proteins handle transport and storage. Transferrin is the primary iron transport protein in blood plasma, binding two atoms of ferric iron per molecule and carrying them to tissues throughout the body, most heavily to the bone marrow where developing red blood cells take up iron through transferrin receptors to build hemoglobin. Under normal conditions, transferrin is only about 20 to 30 percent saturated with iron, leaving substantial reserve capacity to buffer any iron entering the bloodstream and prevent it from existing in a free, reactive form. Transferrin saturation, measured as a percentage, is one of the key clinical indicators doctors use to assess iron status, and values that climb toward and beyond 45 percent are a hallmark of iron overload. Ferritin, by contrast, is the primary intracellular iron storage protein, a hollow spherical shell capable of sequestering thousands of iron atoms in a soluble, non-toxic mineral form within cells of the liver, spleen, and bone marrow. A small amount of ferritin also circulates in the blood, and serum ferritin concentration serves as a widely used clinical proxy for total body iron stores, though it is also an acute-phase reactant that rises with inflammation independent of iron status, which can complicate interpretation. Together, transferrin and ferritin form a two-part safety system: transferrin ensures iron in transit is never free in the plasma, while ferritin ensures iron in storage is never free inside the cell. Hepcidin sits upstream of both, since it determines how much iron ferroportin releases into the transferrin pool in the first place, linking hormonal regulation to the transport and storage systems that keep iron chemically contained at every stage.

When the System Fails: Anemia of Inflammation and Hereditary Hemochromatosis

The hepcidin-ferroportin axis explains two clinically important and opposite disorders of iron balance. Anemia of inflammation, also called anemia of chronic disease, occurs when persistent infection, autoimmune disease, chronic kidney disease, or cancer drives sustained production of inflammatory cytokines, particularly interleukin-6, which stimulates the liver to overproduce hepcidin. The resulting high hepcidin degrades ferroportin on enterocytes and macrophages, blocking dietary iron absorption and, more significantly, trapping recycled iron inside macrophages so it cannot reach the bone marrow. The bone marrow becomes functionally iron-starved even though total body iron stores may be normal or elevated, a pattern clinicians distinguish from true iron-deficiency anemia by finding low transferrin saturation alongside normal or high ferritin. At the opposite extreme, hereditary hemochromatosis is a genetic disorder, most commonly caused by mutations in the HFE gene, that results in inappropriately low hepcidin production relative to the body's iron stores. Without adequate hepcidin to restrain it, ferroportin stays active on the cell surface, and iron absorption continues unchecked even as iron accumulates to dangerous levels in the liver, heart, pancreas, and joints. Left untreated, hereditary hemochromatosis can progress to cirrhosis, liver cancer, diabetes (historically called bronze diabetes due to associated skin pigmentation), cardiomyopathy, and joint disease. Treatment for hemochromatosis exploits the body's lack of an excretory pathway for iron in a direct way: therapeutic phlebotomy, or scheduled blood removal, forces the body to use stored iron to replace lost red blood cells, gradually depleting excess iron stores over months to years. Both conditions illustrate the same underlying principle: because iron cannot be actively excreted, any sustained miscalibration of hepcidin, whether too high or too low, inevitably produces disease.

Frequently asked questions

Try it live

Everything above runs in your browser — open Iron Homeostasis: How Hepcidin Balances Iron Absorption and Storage and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.